Heru’s Re:Vive 2.0 platform to diagnose vision defects using commercially available augmented reality headsets was named an honouree at January’s CES (Consumer Electronics Show) 2022 Innovation Awards.
The platform tests contrast sensitivity; visual fields (with clinical results comparable to the Humphrey perimeter, according to Heru); colour vision, using Ishihara and the Farnsworth D-15 methods; and dark adaptation. A virtual assistant guides the patient through each process.
Dr Mohamed Shousha, Heru’s founder and CEO, said Re:Vive provides physicians with a single, space-saving diagnostic, health and wellness tool that has revolutionised how screening and diagnosis for visual defects is performed. Dr Frederic Moll, chief development officer of robotics at Johnson & Johnson Medical Devices and a Heru advisor, added that such diagnostic technology paves the way for new augmented vision correction applications being developed.
For more, see www.eyeonoptics.co.nz/articles/archive/ai-powered-vision-diagnosis-and-therapy/
